WEKO3
インデックスリンク
アイテム
Suppression of advanced glycation and lipoxidation end products by Angiotensin ii type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension
https://fmu.repo.nii.ac.jp/records/2001839
https://fmu.repo.nii.ac.jp/records/2001839d1b93167-c2a4-4316-af5a-12258ff6f4db
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
FksmJMedSci_59_p69.pdf (364.2 KB)
|
|
| Item type | デフォルトアイテムタイプ（フル）fmu(1) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2014-03-20 | |||||||||||||||
| タイトル | ||||||||||||||||
| タイトル | Suppression of advanced glycation and lipoxidation end products by Angiotensin ii type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension | |||||||||||||||
| 言語 | en | |||||||||||||||
| 作成者 |
Ono, Yoshiaki
× Ono, Yoshiaki
× Mizuno, Kenji
× Takahashi, Michihiko
× Miura, Yukio
× Watanabe, Tsuyoshi
|
|||||||||||||||
| 権利情報 | ||||||||||||||||
| 権利情報 | © 2013 The Fukushima Society of Medical Science | |||||||||||||||
| 内容記述 | ||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||
| 内容記述 | Objective: This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH).Methods: Urinary excretion of pyrraline (PR), pentosidine (PT), acrolein (AC), and 8-hydroxy-2'-deoxyguanosine (8-OH-dG) and microalbuminuria were assessed in patients with DM complicated by EH who were treated with candesartan 4 mg/day for 3 months.Results: In a total of 25 patients urinary excretion of PR (nmol/g· cr), PT (pmol/g· cr), and 8-OH-dG (ng/mg· cr) was significantly (all P < 0.05) decreased from (mean ± SEM) 11.9 ± 1.9, 30.6 ± 2.4, and 7.9 ± 0.6, respectively, at baseline to 8.4 ± 1.4, 27.1 ± 2.0, and 6.9 ± 0.6, respectively, at 3 months. Meanwhile, excretion of AC was unaltered from 209.6 ± 40.0 to 189 ± 24.8 nmol/mgcr (P = NS). Urinary albumin excretion was significantly (P < 0.05) reduced from 27.7 ± 4.6 to 14.1 ± 1.1 mg/g· cr. There were weak but statistically significant positive correlations between the change of urinary 8-OH-dG excretion and that of albumin (r = 0.414; P < 0.05) and change of hemoglobin (Hb) A1c (r = 0.45; P < 0.05).Conclusion: Candesartan exerts protective effect(s) on the cardiovascular system by suppression of oxidative stress-mainly through inhibiting production of advanced glycation end products (AGEs) rather than of advanced lipoxidation end products (ALEs)-in type 2 DM patients with EH. | |||||||||||||||
| 出版者 | ||||||||||||||||
| 出版者 | The Fukushima Society of Medical Science | |||||||||||||||
| 言語 | ||||||||||||||||
| 言語 | eng | |||||||||||||||
| 書誌情報 |
en : Fukushima Journal of Medical Science 巻 59, 号 2, p. 69-75, 発行日 2013 |
|||||||||||||||
| 関連情報 | ||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||
| 関連識別子 | https://doi.org/10.5387/fms.59.69 | |||||||||||||||
| 関連情報 | ||||||||||||||||
| 識別子タイプ | PMID | |||||||||||||||
| 関連識別子 | 24500381 | |||||||||||||||
| 関連情報 | ||||||||||||||||
| 識別子タイプ | ICHUSHI | |||||||||||||||
| 関連識別子 | 2015033198 | |||||||||||||||
| 資源タイプ | ||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||
| 資源タイプ | journal article | |||||||||||||||
| 出版タイプ | ||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||
| 収録物識別子 | ||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||
| 収録物識別子 | 0016-2590 | |||||||||||||||
| 収録物識別子 | ||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||
| 収録物識別子 | 2185-4610 | |||||||||||||||
| 収録物識別子 | ||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||
| 収録物識別子 | AA0065246X | |||||||||||||||
| 主題 | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | type 2 diabetes mellitus (DM) | |||||||||||||||
| 主題 | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | essential hypertension (EH) | |||||||||||||||
| 主題 | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | candesartan | |||||||||||||||
| 主題 | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | advanced glycation end products (AGEs) | |||||||||||||||
| 主題 | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | advanced lipoxidation endproducts (ALEs) | |||||||||||||||
| 主題 | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | microalbuminuria | |||||||||||||||
| 主題 | ||||||||||||||||
| 主題Scheme | Other | |||||||||||||||
| 主題 | oxidative stress | |||||||||||||||
